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Summary In 1983, we reported results from the Oxford Family Planning Association contraceptive study
regarding the association between oral contraceptives (OCs) and cervical neoplasia, after a 10 year follow-up of
a cohort of 17 000 women. Further findings from this study are reported here after an additional 12 years of
follow-up. A nested case-control design was used in which cases were all women diagnosed under 45 years of
age with invasive carcinoma (n= 33), carcinoma in situ (n= 121) or dysplasia (n= 159). Controls were randomly
selected from among cohort members and matched to cases on exact year of birth and clinic attended at
recruitment to study. Conditional logistic regression analysis was used to determine odds ratios (ORs) and 95%
confidence intervals (CIs) associated with various aspects of OC use relative to never users adjusted for social
class, smoking, age at first birth and ever use of diaphragm or condom. Ever users of OCs had a slightly
elevated OR for all types of cervical neoplasia combined (OR= 1.40, 95% CI 1.00- 1.96). Odds ratios were
highest for invasive carcinoma (OR=4.44, 95% CI 1.04-31.6), intermediate for carcinoma in situ (OR= 1.73,
95% CI 1.00-3.00) and lowest for dysplasia (OR= 1.07, 95% CI 0.69- 1.66). The elevated risk associated with
OC use appeared to be largely confined to current or recent (last use in the past 2 years) long-term users of
OCs. Among current or recent users, ORs for all types of cervical neoplasia combined were 3.34 (95% CI
1.96-5.67) for 49-72 months of use, 1.69 (95% CI 0.97-2.95) for 73-96 months and 2.04 (95% CI 1.34-
3.11) for 97 or more months. These results suggest a possible effect of OC use on later stages of cervical
carcinogenesis, although residual confounding due to sexual factors or human papillomavirus (HPV) infection
cannot be ruled out.
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In 1983, we described the association between carcinoma of
the cervix and use of oral contraceptives (OCs) in a cohort of
17 000 women [the Oxford Family Planning Association
(FPA) contraceptive study] after a 10 year follow-up period
(Vessey et al., 1983). At that time, 13 cases of invasive cancer
of the cervix had occurred during the 65 101 woman-years
of follow-up for women who had entered the study as OC
users, but no cases were found during the 26 432 woman-
years of follow-up for those who had entered the study as
intra-uterine device (IUD) users. Both carcinoma in situ and
dysplasia also occurred more frequently among OC users
than among IUD users (with relative risks of 1.60 and 1.45
respectively) and there was a statistically significant increas-
ing trend in incidence of all cervical neoplasia combined with
increasing duration of OC use (P<0.05).
The previous analyses were based on relatively small
numbers of events (a total of 136 cases for all cervical
neoplasia combined). In the subsequent 12 years, a further
321 cases of cervical neoplasia have accrued, resulting in a
total of 457 cases. We report here the association between
oral contraceptive use (and use of other methods of
contraception) and cervical neoplasia in 310 cases diagnosed
under 45 years of age and 3091 matched controls identified
from cohort members.
Materials and methods
A detailed description of the Oxford FPA study has been
given elsewhere (Vessey et al., 1976). In brief, 17 032 women
were recruited at 17 large family planning clinics in England
and Scotland between 1968 and 1974. At the time of
recruitment, each woman had to be: (1) aged 25-39 years,
(2) married, (3) white and British, (4) willing to cooperate
and (5) either a current user ofOCs for at least 5 months or a
current user of a diaphragm or an IUD for at least 5 months
without previous exposure to OCs. Information collected at
entry to the study included date of birth, age at marriage,
social class of husband, smoking habits, weight and height,
contraceptive history and obstetric and medical history.
During the annual clinic follow-up of each woman,
information was recorded by a doctor or nurse about
pregnancies and their outcome, changes in contraceptive
practice, referrals to hospital and the frequency and outcome
of cervical cytological examinations carried out at the clinic.
Diagnoses on discharge from hospital were confirmed by
obtaining copies of discharge letters, summaries and pathol-
ogy reports. Women who stopped attending the clinic were
sent a postal questionnaire annually, or, if this was not
returned, were interviewed by telephone or during a home
visit. The work was coordinated by a research assistant in each
clinic. Loss to follow-up because women were untraced or
refused to continue to cooperate was about 0.4% per annum.
In the nested case-control study reported here, cases were
all women aged under 45 years who were diagnosed during
follow-up as having histologically proven invasive cervical
carcinoma (ICD 8th Revision 180.0), carcinoma in situ (ICD
8th Revision 234.0) or dysplasia (ICD 8th Revision 621.9,
modified for the Oxford FPA study). We used the old
nomenclature to describe the different types of non-invasive
cervical neoplasia because many of the data were collected
before the term 'cervical intraepithelial neoplasia' was widely
used. Of the 326 cases potentially eligible for inclusion in the
analysis, 16 were excluded because age at first birth was not
known, leaving a total of 310 cases. Three cases were
diagnosed on two separate occasions as having different types
of cervical neoplasia: one with dysplasia followed by
carcinoma in situ, the other two with carcinoma in situ
followed by dysplasia. These women were included as cases in
both diagnostic groups when analysed separately but, in
analyses of all cervical neoplasia combined, data for the first
diagnosis only were included.
For each case, up to ten controls were randomly selected
from other cohort members with the same year of birth
attending the same clinic at recruitment as the case. Women
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who had undergone hysterectomy before the date of
diagnosis of their matched case, or for whom age at first
birth was not known, were not eligible as controls. The same
control could be chosen for more than one case, and cases
were eligible as potential controls for other cases before their
date of diagnosis.
Information about use ofthe major forms ofcontraception
was obtained during the follow-up (OC, IUD, diaphragm,
condom, tubal sterilisation of woman and vasectomy of
husband). Cases and controls were categorised as to whether
they were ever or never users of each of these methods.
Different aspects ofOC use were grouped into a limited number
of categories for the analysis: total duration of use and time
since last use in six categories (less than 13, 13 -24, 25-48, 49-
72, 73 -96 and 97 months or more); time since first use in four
categories (less than 60, 61 - 120, 121 - 180 and 181 months or
more); age at first use in four categories (less than 24, 24-25,
26-27, 28 years or older); calendar year of first use in three
categories (before 1968, 1968 - 1969 and 1970 or later).
Data on a number of potential confounding variables
(social class of husband, current cigarette smoking and age at
first marriage) were obtained only at entry to the study,
whereas information about induced abortion and miscarriage
was collected only during follow-up; data about age at first
birth and parity were collected both at entry and during
follow-up. For these variables the groups used were as
follows: social class of husband (based on the British
Registrar General's classification) in three categories (classes
I +II, class III and classes IV+V together with unemployed,
armed services, students); current cigarette smoking in three
categories (non-smokers, 1-14 cigarettes per day and > 15
cigarettes per day); age at first marriage in four categories
(less than 20, 20-21, 22-23 and 24 years or more); induced
abortion or miscarriage both in two categories (never and
ever); age at first birth in five categories (less than 20, 20-21,
22-23, 24-25 and 26 years or more); and parity in four
categories [three or more births, two births, one birth and no
births (nulliparous)].
Statistical analysis
Conditional logistic regression analysis (Breslow and Day,
1980) was used to obtain maximum likelihood estimates of
odds ratios (ORs) for the various comparisons, with
adjustment for social class, smoking and age at first birth
because these variables are recognised as well-established risk
factors for cervical neoplasia (Swan and Petitti, 1982;
Greenberg et al., 1985). ORs according to contraceptive
method were calculated relative to never users with additional
adjustment for ever use of OCs, diaphragm or condom (as
appropriate) since associations between these three contra-
ceptive methods and cervical neoplasia are also well
established (Swan and Petitti, 1982). Confidence intervals
(95% CIs) were derived from the standard errors for model
coefficients and checked using likelihood-based estimation;
because of the small numbers of invasive cancers, however,
all 95% confidence intervals for this group were likelihood
based. Approximate chi-square statistics for trend or
differences in ORs across categories were derived from
likelihood-ratio test statistics. Tests for trend in ORs with
increasing level of OC use (e.g. duration of use) were
calculated with inclusion in the baseline logistic regression
model of a term to represent never/ever use of OCs. Logistic
regression analyses were performed using the statistical
packages EPICURE (Hirosoft International Corporation,
1990) and EGRET (Statistics and Epidemiological Research
Corporation, 1989).
Results
There were 33 cases of invasive cancer, 121 cases of
carcinoma in situ and 159 cases of dysplasia. After allowing
for the three duplicate cases, this yielded a total of 310 cases
for all cervical neoplasia combined. Ten controls were
successfully selected for each case, the only exception being
one case of invasive cancer where only one control was
available. Of the 33 invasive cancer cases, three had
adenocarcinoma (one a clear cell tumour), three had
adenosquamous carcinoma, 24 had squamous carcinoma
and three were of unspecified type.
Of the potential confounding variables examined in Table
I, age at first birth and smoking were both strongly related to
risk of all cervical neoplasia combined. Women who were
aged 26 or older at their first birth were only 0.29 times as
likely to have cervical neoplasia as women who were aged 19
or younger. The decreasing trend in odds ratios with
increasing age at first birth was highly significant
(P<0.0001). Heavy smokers (15+ cigarettes per day) had a
2-fold increase in risk of developing cervical neoplasia
compared with non-smokers and a highly significant trend
of increasing OR was observed across the smoking categories
(P<0.0001). The above patterns were also seen for the
individual cancer diagnoses.
Women who had an induced abortion during follow-up
were at significantly higher overall risk of developing cervical
neoplasia than those not having an induced abortion
(OR= 1.78, P<0.04). This association was significant for
cervical dysplasia alone but not for the other diagnoses.
Women who had a miscarriage during follow-up did not
appear to be at increased risk of cervical neoplasia. Social
class, parity and age at marriage were not significantly related
to cervical neoplasia overall, but there was a higher risk of
carcinoma in situ in the lower social class groups.
After adjustment for age at first birth, smoking and social
class, women who were diaphragm users at entry to the study
had a significantly lower risk of all cervical neoplasia
combined than OC users (OR=0.48, 95% CI 0.32-0.72)
but little difference was observed between women who were
IUD users and OC users at entry to study (OR=0.98, 95% CI
0.71-1.37) (results not shown). Ever users of OCs had a
slightly higher overall risk ofcervical neoplasia compared with
never users (OR=1.62, 95% CI 1.19-2.22) but when
additional adjustment was made for ever use of diaphragm
or condom, the overall OR was reduced to 1.40 (Table II).
Within diagnostic groups the corresponding ORs were highest
for invasive cancer (OR =4.44), intermediate for carcinoma in
situ (OR= 1.73) and lowest for dysplasia (OR = 1.07). Ever use
of an IUD also appeared to be associated with a slightly
increased overall risk of cervical neoplasia (OR= 1.38) and of
invasive cancer in particular (OR=4.49).
Ever use of the diaphragm was associated with a lower
risk for all cervical neoplasia combined (OR = 0.62), and this
reduced risk was evident in the three diagnostic subgroups.
Vasectomy was also associated with a lower risk overall, but
here the effect appeared strongest for invasive cancer
(OR = 0.17). Tubal sterilisation was associated with a
significantly reduced risk of dysplasia but not of carcinoma
in situ or invasive cancer and the effect was not significant for
all cervical neoplasia combined. Use of condoms did not
appear to affect the risk of cervical cancer.
In further analyses of all cervical neoplasia combined, we
additionally adjusted ORs for each contraceptive method for
use of all the other contraceptive methods and also for ever
having had an induced abortion during follow-up (results not
shown). This caused the relative risk estimate for ever users
of OCs to increase slightly from 1.40 to 1.70 (95% CI 1.18-
3.38), whereas that for ever use of an IUD reduced from 1.38
to 1.28 (95% CI 0.95-1.72) and was no longer statistically
significant. Tubal sterilisation became significantly associated
with a reduced risk (OR=0.60, 95% CI 0.40-0.90). No
important changes were observed for the other contraceptive
methods.
Total duration of OC use did not appear to be a strong
risk factor for cervical neoplasia, although significantly
elevated risks were observed in the categories of longer use
(49 months or more) (Table III). Of the six cases with
invasive adenocarcinoma or adenosquamous carcinoma ofOral contraceptives and cervical cancer
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Table I Odds ratios (ORs) and 95% confidence intervals (CIs) for different categories ofcervical neoplasia according to potential confounding
variables
Invasive In situ Dysplasia All cervical neoplasia
(33 case-control sets) (121 case-control sets) (159 case-control sets) (310 case-control sets)
Variable Casesa OR (95% CI)b Casesa OR (95% CI)b Casesa OR (95% CI)b Casesa OR (95% CI)b
Social class
I -II
III
IV-V
x2 for trend (d.f. = 1)
P-value
Smoking
Non-smokers
1 - 14 cigarettes per day
15+ cigarettes per day
x2 for trend (d.f. = 1)
P-value
Parity
3 + births
2 births
1 birth
Nulliparous
x2 for trend (d.f.= 1)
P-value
Age at marriage (years)
s 19
20-21
22-23
24+
X2 for trend (d.f.
= 1)
P-value
Age at first birthc (years)
<19
20-21
22-23
24-25
26 +
Nulliparous
%2 for trend (d.f. 1)
P-value
Induced abortiond
Never
Ever
x2 for difference (d.f.= 1)
P-value
Miscarriaged
Never
Ever
x2 for difference (d.f.= 1)
P-value
13
15
S
16
4
13
15
8
8
2
14
11
3
S
10
8
6
3
4
2
1.0
0.52 (0.20- 1.30)
0.41 (0.10-1.41)
2.36
0.1
1.0
0.78 (0.25-2.50)
3.05 (1.27-7.28)
5.27
0.02
1.0
0.67 (0.23-1.86)
3.89 (1.07-14.7)
0.15 (0.02-0.78)
2.34
0.1
1.0
0.97 (0.31 -3.20)
0.64 (0.09-3.72)
1.24 (0.18-8.69)
0.06
0.9
1.0
0.51 (0.13-0.93)
0.32 (0.03-0.38)
0.15 (0.02-0.71)
0.09 (0.02-0.36)
0.12 (0.02-0.68)
12.9
<0.001
32 1.0
1 0.66 (0.04-3.53)
0.18
0.7
33 1.0
0 0.00 (0.00-c)
2.45
0.1
30
72
19
62
32
27
39
51
19
12
38
34
28
21
21
25
19
20
24
12
1.0
1.75 (1.10-2.78)
1.94 (1.03-3.66)
5.66
0.02
1.0
1.88 (1.19-2.98)
1.77 (1.08-2.92)
6.97
0.008
1.0
0.88 (0.54- 1.41)
0.94 (0.50-1.78)
0.43 (0.19-0.99)
0.07
0.8
1.0
0.96 (0.52- 1.77)
1.09 (0.53-2.26)
1.07 (0.47-2.41)
0.07
0.8
1.0
0.68 (0.35-1.31)
0.45 (0.23-0.88)
0.56 (0.28-1.10)
0.26 (0.13-0.51)
0.45 (0.20-1.01)
14.4
0.005
116 1.0
5 1.72 (0.60-4.92)
0.95
0.3
111 1.0
10 1.56 (0.76-3.20)
1.37
0.2
66
77
16
86
37
36
41
81
23
14
43
46
44
26
27
24
37
18
39
14
1.0
0.77 (0.54-1.12)
0.70 (0.39- 1.26)
2.25
0.1
1.0
1.76 (1.17-2.66)
1.91 (1.24-2.94)
10.7
<0.001
1.0
1.07 (0.70- 1.65)
0.92 (0.52-1.64)
0.52 (0.25- 1.11)
0.04
0.9
1.0
1.10 (0.63-1.95)
1.39 (0.73-2.66)
1.11 (0.53-2.30)
0.18
0.7
1.0
0.61 (0.33-1.13)
0.67 (0.39-1.16)
0.42 (0.22-0.81)
0.38 (0.21-0.67)
0.51 (0.25-1.06)
9.25
0.002
145 1.0
14 2.49 (1.34-4.63)
7.12
0.008
152 1.0
7 0.73 (0.33- 1.64)
0.62
0.4
107
164
39
161
73
76
94
139
50
27
95
90
73
52
58
57
61
41
66
27
1.0
1.04 (0.79- 1.36)
0.99 (0.66-1.49)
0.01
0.9
1.0
1.71 (1.27-2.30)
1.96 (1.45-2.64)
22.1
<0.0001
1.0
0.94 (0.70-1.26)
1.06 (0.71-1.57)
0.43 (0.25-0.72)
0.03
0.9
1.0
1.01 (0.69-1.49)
1.13 (0.71-1.79)
1.06 (0.63- 1.77)
0.11
0.7
1.0
0.64 (0.42-0.96)
0.54 (0.37-0.81)
0.44 (0.28-0.68)
0.29 (0.19-0.44)
0.43 (0.26-0.72)
32.0
<0.0001
291 1.0
19 1.78 (1.06-2.99)
4.23
0.04
293 1.0
17 0.96 (0.57-1.63)
0.02
0.9
aNumber ofcases in each category. For all variables all case-control sets contributed information to all the analyses. bAdjusted for social class,
smoking and age at first birth. cNulliparous women were excluded from the trend analyses. dOccurring during follow-up (pre-study data not
available).
the cervix, four fell into these categories of duration of use.
With regard to time since last use, highest risks were observed
in current or recent users of OCs, the excess being
particularly evident for invasive cancers (OR for use in the
last 24 months =6.81). The trend of decreasing risk with
increasing time since last use was statistically significant for
all cervical neoplasia combined (P<0.0001) and separately
for invasive cancer (P=0.006) and dysplasia (P=0.005). Risk
was not significantly associated with time since first use, age
at first use or calendar year of first use either for all cervical
neoplasia combined or for any of the individual cervical
neoplasia categories (results not shown).
ORs for all cervical neoplasia combined were additionally
adjusted for ever use of all other contraceptive methods and
for ever having undergone induced abortion during the
follow-up period (results not shown). This slightly increased
the ORs associated with longer duration of OC use
(OR=2.17, 95% CI 1.38-3.41 for 49-72 months' dura-
tion; OR= 1.68, 95% CI 1.04-2.70 for 73-96 months; and
OR= 2.14, 95% CI 1.38-3.30 for 97+months) and there was
a statistically significant trend overall with increasing
duration of use (P=0.04). No important changes were
observed for the other variables examined in Table III when
these additional adjustments were made.
Table IV shows the joint effect ofduration of use and time
since last use of OCs on risk for all cervical neoplasia
combined. Highest relative risks were observed for current/
recent users of OCs (last use up to 24 months in the past)
who had used OCs for a total of 49 months or more
(OR= 3.34 for 49-72 months duration of use; OR= 1.69 for
73-96 months; and OR=2.04 for 97+months). Additional
adjustment for ever use of all other contraceptive methods
and for ever having undergone an induced abortion during
the follow-up period resulted in slightly higher risk estimates,
the corresponding ORs being 4.03, 2.02, and 2.53,
respectively. Unfortunately, we were unable to perform
these analyses separately for the three diagnostic categories
as a consequence of small numbers of cases in the
subcategories of duration and time since last use combined.
We examined the association between risk of cervicalOral contraceptives and cervical cancer
00 KT Zondervan et al
1294
Table II Odds ratios (ORs) and 95% confidence intervals (CIs) for different categories ofcervical neoplasia according to different methods of
contraception
Invasive In situ Dysplasia All cervical neoplasia
(33 case-control sets) (121 case-control sets) (159 case-control sets) (310 case-control sets)
Variable Casesa OR (95% CI)b Casesa OR (95% CI)b Casesa OR (95% CI)b Casesa OR (95% CI)b
Oral contraceptives
Never 2 1.0 22 1.0 35 1.0 59 1.0
Ever 31 4.44 (1.04-31.6) 99 1.73 (1.00-3.00) 124 1.07 (0.69-1.66) 251 1.40 (1.00-1.96)
x2 for difference (d.f. = 1) 4.05 (P=0.04) 3.97 (P=0.05) 0.08 (P=0.8) 4.04 (P=0.04)
Intra-uterine device
Never 19 1.0 82 1.0 101 1.0 199 1.0
Ever 14 4.49 (1.66-13.0) 39 0.86 (0.53-1.41) 58 1.49 (0.99-2.23) 111 1.38 (1.03-1.84)
x2 for difference (d.f. = 1) 8.86 (P=0.003) 0.35 (P=0.6) 3.71 (P=0.05) 4.55 (P =0.03)
Diaphragm
Never 31 1.0 106 1.0 130 1.0 264 1.0
Ever 2 0.34 (0.05-1.33) 15 0.59 (0.32-1.09) 29 0.64 (0.40-0.99) 46 0.62 (0.43-0.88)
x2 for difference (d.f. =l) 2.28 (P=0.1) 3.13 (P=0.08) 3.95 (P=0.05) 7.80 (P=0.005)
Condom
Never 20 1.0 71 1.0 102 1.0 193 1.0
Ever 13 0.83 (0.34-1.99) 50 1.18 (0.77-1.81) 57 0.96 (0.66-1.40) 117 1.00 (0.76-1.30)
x2 for difference (d.f.= 1) 0.18 (P=0.7) 0.59 (P=0.4) 0.05 (P=0.8) 0.001 (P= 1.0)
Vasectomy
Never 31 1.0 101 1.0 134 1.0 264 1.0
Ever 2 0.17 (0.02-0.70) 20 0.71 (0.42-1.21) 25 0.66 (0.41-1.05) 46 0.62 (0.44-0.88)
x2 for difference (d.f.= 1) 6.50 (P=0.01) 1.65 (P=0.2) 3.26 (P=0.07) 7.93 (P=0.005)
Tubal sterilisation
Never 29 1.0 103 1.0 146 1.0 275 1.0
Ever 4 0.73 (0.16-2.46) 18 1.13 (0.63-2.01) 13 0.51 (0.27-0.94) 35 0.73 (0.49-1.09)
x2 for difference (d.f. = 1) 0.22 (P=0.6) 0.17 (P=0.7) 5.27 (P=0.02) 2.50 (P=0.1)
aNumber of cases in each category. For all variables all case-control sets contributed information to all the analyses. bOdds ratios and 95%
confidence intervals adjusted for social class, smoking, age at first birth, ever use ofOC, diaphragm and condom.
Table Ill Odds ratios (ORs) and 95% confidence intervals (CIs) of different categories of cervical neoplasia according to factors related to
oral contraceptive use
Invasive In situ Dysplasia All cervical neoplasia
(33 case-control sets) (121 case-control sets) (159 case-control sets) (311 case-control sets)
Variable Casesa OR (950% CI)b Casesa OR (95% CI)b Casesa OR (95% CI)b Case? OR (95% CI)b
Total duration
of OC use (months)
Never 2 1.0 22 1.0 35 1.0 59 1.0
1-12 4) 4 1.41 (0.45-4.40) 5 0.79 (0.30-2.14) 13 1.37 (0.72-2.61)
13-24 0 5.45 (0.79- 50.5) 7 1.75 (0.67-4.59) 5 0.68 (0.24-1.89) 12 1.09 (0.55-2.15)
25-48 2 20 1.71 (0.84-3.48) 11 0.52 (0.25-1.10) 32 0.96 (0.59-1.55)
49-72 41 2.77 (0.49-23.1) 18 1.48 (0.73-3.03) 34 1.75 (1.02-3.02) 54 1.66 (1.09-2.54)
73-96 5) 11 1.15 (0.52-2.56) 26 1.22 (0.68-2.19) 42 1.31 (0.84-2.04)
97 + 16 4.65 (1.08-32.9) 39 2.47 (1.30-4.68) 43 1.06 (0.62-1.80) 98 1.66 (1.13-2.45)
x2 for trend (d.f.=1)c 0.06 1.35 1.84 3.15
P-value 0.8 0.2 0.2 0.08
Months since
last use of OCs
Never 2 1.0 22 1.0 35 1.0 59 1.0
Current-12 20) 45 2.22 (1.20-4.12) 59 1.70 (1.02-2.83) 124 2.23 (1.53-3.24)
13-24 1i 6.81 (1.56-49.2) 2 0.56 (0.12-2.54) 7 0.98 (0.40-2.40) 10 0.76 (0.36-1.58)
25-48 3) 12 1.81 (0.79-4.14) 10 0.53 (0.25-1.14) 24 0.92 (0.54-1.56)
49-72 3f 2.56 (0.43-21.3) 12 1.95 (0.86-4.42) 16 1.05 (0.54-2.04) 29 1.25 (0.76-2.08)
73-96 3) 9 1.45 (0.59-3.57) 12 0.79 (0.38-1.65) 24 1.09 (0.64-1.87)
97+ 1i 1.30 (0.19-11.7) 19 1.26 (0.59-2.70) 20 0.71 (0.36-1.39) 40 0.83 (0.51-1.34)
x2 for trend (d.f. = 1)C 7.63 1.69 7.95 17.2
P-value 0.006 0.2 0.005 <0.0001
aNumber ofcases in each category. For all variables all case-control sets contributed information to all the analyses. bAdjusted for socal class,
smoking, age atfirst birth, everdiaphragm useandevercondom use. cTrend in odds ratios across categories ofever users (see Materials and methods
for details).
neoplasia and type of OC used by women at entry to the
study and the most recent type of OC used in the 12 months
before diagnosis. Of the 219 cases of cervical neoplasia who
were OC users at entry, 209 were using OCs containing 50 Mg
oestrogen and seven were using high-oestrogen dose OC types
(3> 100 jg oestrogen). The risk of all cervical neoplasia
combined for 50 Mg OCs (adjusted for age at first birth,
smoking, social class and ever use of the diaphragm or
condom) was similar to that for non-users at entry
(OR= 1.07, 95% CI 0.78-1.47). Women using high-
oestrogen combined OCs, however, appeared to have an
elevated risk compared with non-users (OR= 2.62, 95% CI
0.99-6.96). For the 124 cases who had used OCs in the 12
months before diagnosis, two had last used one of unknown
type, 25 had last used a progestogen only type, one had last
used a combined type with > 100 Mg oestrogen, 65 had last
used combined OCs with 50 Mg oestrogen and 31 had last
used combined OCs with < 50 Mg oestrogen. The correspond-Oral contraceptives and cervical cancer
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ing adjusted odds ratios for these groups (relative to never
users) were 2.00 (95% CI 1.02-3.92) for progestogen only,
9.11 (95% CI 0.50-166.0) for combined OCs with > 100 jig
oestrogen, 1.87 (95% CI 1.11-3.14) for 50 ug oestrogen and
1.53 (95% CI 0.85-2.73) for <50 yg oestrogen.
An important potential confounding variable which we
could not take into account in the main analyses was
frequency of cervical cytological smearing, as smear data
were available only for the period of follow-up in the clinic.
It was, however, possible to investigate at least in part the
extent to which smear frequency might have affected the
findings for OC use. Approximately 20% of both cases and
controls were being followed up in the clinic at the date of
diagnosis of the case and the median period of follow-up in
the clinic was only slightly higher for cases than for controls
(28 vs 24 months). Little difference was observed between
cases and controls in median months of follow-up in the
clinic until the first suspicious smear (if any was detected) (26
vs 24 months). Examination of smear frequency in 2647
control women with some clinic follow-up indicated no
important differences between those using different methods
of contraception at entry (not shown), ever/never use of OCs
or different categories of time since last use of OCs (Table V).
There was, however, a highly significant association between
total duration of OC use and average interval between clinic
smears (X2=123, d.f.=18, P<0.0001) with a lower percen-
tage of long-term users never having had a clinic smear
(19.7% for 73-96 months and 14.9% for 97+ months
compared with 25.8% for never users). However, after
adjusting for time followed up in clinic until first suspicious
smear (categorised in quartiles: 1 - 12, 13 -26, 27 -58 and
59 + months), no significant association was observed
between duration of OC use and average clinic smear
interval (x2=9.3, d.f.= 18, P=0.95). No differences in
average smear interval were observed for other methods of
contraception among controls with clinic follow-up (results
not shown), apart from the fact that ever sterilised women
had a lower smearing frequency than never sterilised women
X2=l 113 d.f.=3, P=0.01).
Discussion
In this nested case-control study ofcervical cancer in women
diagnosed before 45 years of age, ever users of OCs were
found to be at an increased overall risk compared with never
Table IV Odds ratios for all cervical neoplasia combined (relative to never users) according to total duration ofOC use and time since last OC
use considered together
Total duration of OC use (months)
1-24 25-48 49- 72 73-96 97+ Total
OR OR OR OR OR OR
Variable Casesa (95% CI)b Casesa (95% CI) Casesa (95% CI)b Casesa (95% CI) Casega (95% CI)b Casesa (95% CI)b
Time since last use
(months)
Current-24 7 1.14 10 0.91 32 3.34 22 1.69 63 2.04 134 1.90
(0.46-2.79) (0.43-1.94) (1.96-5.67)* (0.97-2.95)t (1.34-3.11)$ (1.32-2.74)**
25-72 2 0.57 9 1.46 14 1.71 8 1.03 20 0.92 53 1.10
(0.13-2.42) (0.68-3.17) (0.90-3.26)t (0.47-2.29) (0.52- 1.64) (0.72- 1.69)
73 + 16 1.42 13 0.81 8 0.52 12 1.00 15 1.23 64 0.94
(0.75-2.68) (0.42- 1.58) (0.24- 1.15) (0.50-2.03) (0.63-2.41) (0.61-1.45)
Total 25 1.22 32 0.96 54 1.67 42 1.31 98 1.66 251 1.40
(0.73-2.04) (0.59- 1.55) (1.09-2.55)t (0.84-2.05) (1.13-2.46)11 (1.00- 1.96)***
aNumber of cases in each subcategory. bAdjusted for social class, age at first birth, smoking, ever use ofdiaphragm and ever use of condom.
x2 = 19.9 (P<0.001), tx2 =3.4 (P =0.07), :X2 = 11.0 (P< 0.001), **x2=12.0 (P<0.001), ttX2 =5.61 (P =0.02), tTX2 =6.62 (P=0.01), ***X2 =4.04
(P=0.04). All other P-values were >0.1.
Table V Number of controls with a clinic follow-up (n = 2647) according to average interval between smears and method of contraception
(row percentage in parentheses)
Average smear interval'
Variable 1 year 2-3 years 4+ years Never smear Total (100%)
Total number 1005 811 158 673 2647
OC use*
Never 257 (38.5%) 198 (29.6%) 41 (6.1%) 172 (25.8%) 668
Ever 748 (37.8%) 613 (31.0%) 117 (5.9%) 501 (25.3%) 1979
Total duration of OC use
(months)l
Never 257 (38.5%) 198 (29.6%) 41 (6.1%) 172 (25.8%) 668
1-12 29 (31.2%) 22 (23.7%) 6 (6.5%) 36 (38.7%) 93
13-24 41 (35.0%) 20 (17.1%) 1 (0.9%) 55 (47.0%) 117
25-48 147 (37.5%) 93 (23.7%) 15 (3.8%) 137 (35.0%) 392
49-72 151 (38.9%) 110 (28.4%) 19 (4.9%) 108 (27.8%) 388
73-96 139 (37.6%) 136 (36.8%) 22 (6.0%) 73 (19.7%) 370
97+ 241 (38.9%) 232 (37.5%) 54 (8.7%) 92 (14.9%) 619
Time since last OC use
(months)$
Never 257 (38.5%) 198 (29.6%) 41 (6.1%) 172 (25.8%) 668
Current- 12 276 (39.3%) 216 (30.8%) 35 (5.0%) 175 (24.9%) 702
13-24 49 (36.3%) 43 (31.9%) 10 (7.4%) 33 (24.4%) 135
25-48 99 (36.4%) 92 (33.8%) 21 (7.7%) 60 (22.1%) 272
49-72 95 (39.3%) 71 (29.3%) 13 (5.4%) 63 (26.0%) 242
73-96 75 (35.9%) 67 (32.1%) 15 (7.2%) 52 (24.9%) 209
97+ 154 (36.8%) 124 (29.6%) 23 (5.5%) 118 (28.2%) 419
aComputed as follow-up period in clinic before any suspicious smear divided by number ofnormal smears in thatperiod. Controls without any
clinic follow-up were excluded (n =444). bNumber of controls (row percentage). *%2 0.43, d.f. =3, P=0.9; tX 123, d.f. = 18, P<0.0001;
tx2=9.58, d.f.=18,P=0.9.Oral contraceptives and cervical cancer
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users, with excess risks appearing to be highest for invasive
cancer, intermediate for carcinoma in situ and lowest for
dysplasia. Ever use ofthe diaphragm, female tubal sterilisation
and vasectomy of the husband were associated with a reduced
overall risk of cervical neoplasia, whereas ever use of IUDs
was associated with a slightly increased overall risk of the
disease. For OC use, the increased risk was largely confined to
recent, long-term users. Long-term use in the past (when OCs
had been stopped more than 24 months before date of
diagnosis) did not seem to be associated with an increased
risk. All risk estimates were adjusted for variables that were
defined a priori as having important potential confounding
effects: smoking, social class, age at first birth and ever use of
diaphragm or condom. Additional adjustments for ever use of
other contraceptive methods and for ever having undergone
an induced abortion during follow-up tended to strengthen the
significance of the results for OCs.
Long-term and/or recent OC use have been associated
separately with an increased risk of invasive cervical
carcinoma and carcinoma in situ in the Royal College of
General Practitioners' cohort study (Beral et al., 1988).
Similar findings have been reported from several large case-
control studies that examined the relationship between OCs
and invasive cancer (WHO, 1985, 1993; Brinton et al., 1986,
1987; Parazzini et al., 1990) or carcinoma in situ (Irwin et al.,
1988; Jones et al., 1990; Kjaer et al., 1993; Ye et al., 1995).
Some smaller studies have reported no significant findings for
long-term or recent OC use in relation to invasive cancer
(Peters et al., 1986; Ebeling et al., 1987; Irwin et al., 1988;
Cuzick et al., 1989) or carcinoma in situ (Molina et al., 1988;
Becker et al., 1994), and it has been suggested that the
previously reported results relating OC use to cervical
neoplasia were caused by detection bias and lack of control
for confounding (Irwin et al., 1988). Two large case-control
studies investigated the combined effect of duration and
recency of OC use on risk ofinvasive carcinoma of the cervix
(Brinton et al., 1990; WHO 1993). In agreement with our
results, these studies also reported the highest relative risks in
current/recent, long-term users of OCs. Results concerning
the association between OC use and the risk of dysplasia
have been inconclusive (Negrini et al., 1990; De Vet et al.,
1993). Our results suggest that OC use may not be as strongly
associated with risk of dysplasia as with risk of invasive
carcinoma or carcinoma in situ.
In this study we also observed a reduced risk of cervical
neoplasia associated with use of the diaphragm, female tubal
sterilisation and vasectomy of the husband. Use of barrier
methods has been reported consistently as a protective factor
for cervical cancer in previous studies (Parazzini et al., 1989;
Coker et al., 1992). Unexpectedly, we found no effect ofuse of
the condom. A likely explanation for this is that condom users
relied on this contraceptive method for relatively short periods
of time compared with diaphragm users, since none of the
women relying on condoms were using this method at entry to
the study. A protective effect of female tubal sterilisation and
of vasectomy has also been reported previously (Swan and
Brown, 1979, 1981). The possible effect of the latter method
has been interpreted as being due to the removal of sperm
basic proteins that have been suggested as playing a role in
cervical carcinogenesis (Reid et al., 1978).
The significantly increased risk of cervical neoplasia for
ever users of IUDs that was most evident for invasive
carcinoma (Table II), appeared to be largely explained by the
influence of other contraceptive methods and the effect of
induced abortion during follow-up. Most other studies that
have investigated IUD use have found no significant effect on
cervical neoplasia (Peters et al., 1986; Cuzick et al., 1989;
Lassise et al., 1991), although a protective effect has been
reported in two (Molina et al., 1988; Brinton et al., 1990).
In ourprevious cohort analysis we reported that nine out of
13 cases of invasive cervical cancer were found among long-
term OC users (more than 72 months of use), that both
carcinoma in situ and dysplasia also occurred more frequently
in the oral contraceptive entry group than in the IUD entry
group, and that there was a significant trend in incidence ofall
three forms of cervical neoplasia combined with increasing
duration of OC use (Vessey et al., 1983). The present nested
case-control study has several advantages over the previous
cohort analysis and over case-control studies that are not
nested within a cohort. Compared with our previous analysis,
there has been a large increase in the number of cases
available, which has made the present analyses more stable
and the findings less likely to be due to chance. The case-
control approach enabled us to consider OC use in much more
detail than before, while adjusting for a number of important
potential confounding variables. Furthermore, unlike non-
nested case-control studies, the data in contraceptive use and
confounding variables were collected during annual follow-up
and were therefore much less prone to recall bias.
One limitation of our study was that we were unable to
adjust for the potentially important confounding effects of
number of sexual partners and age at first intercourse. We did
adjust for the effect of age at first birth (which was strongly
related to cervical neoplasia risk) which, in this cohort of
women married for the most part in the 1960s or earlier, may
have been closely related to age at first intercourse. Age at
marriage, which might also be expected to be related to factors
such as age at first intercourse and number of sexual partners,
was not related to cervical cancer risk in this study after
adjustment for age at first birth (Table I). Data collected in
1977 for a small subset of women in the cohort (58 with
cervical neoplasia and 139 matched controls) found that
women who were IUD users or OC users at entry did not
differ with respect to age at first intercourse or number of
sexual partners, whereas diaphragm users at entry were less
likely to have had intercourse at an early age and had had
fewer sexual partners (Wright et al., 1978). All women who
entered the study were married, and the majority (69%)
reported having had only one sexual partner. Strong
confounding by number of sexual partners or age at first
intercourse therefore seems unlikely in this study, although we
cannot rule out the possibility that some residual confounding
owing to these factors may have influenced the results.
Recently, infection with some subtypes of the human
papillomavirus (16 and 18 in particular) has been strongly
associated with risk of invasive cervical cancer in two case-
control studies (Bosch et al., 1992; Eluf-Neto et al., 1994).
These studies, however, were conducted in settings where the
prevalence of HPV infection of women was relatively high.
Owing to very small numbers of HPV-negative cases and
HPV-positive controls the independent effect of OC use on
risk of cervical cancer could not be accurately determined.
Risk of HPV infection is strongly associated with early age at
first intercourse and in particular with the number of sexual
partners (Eluf-Neto et al., 1994). As mentioned earlier, the
majority of the women in our study were likely to have had
only one sexual partner and therefore the risk of HPV
infection in these women may be relatively low. It should be
noted, however, that we have no data at all on number of
sexual partners of the husband that may have influenced the
risk of HPV infection for the women in this study.
It was not possible to adjust our results for frequency of
cervical cytological smearing since these data were available
only during clinic follow-up. We were able, however, to
investigate the potential confounding effect of this variable to
some extent by examining the association between the
average smear interval during clinic follow-up and use of
oral and other methods of contraception using data for
controls. Long-term users of OCs (over 72 months) had at
least one clinic smear significantly more frequently than never
or short-term users, but after adjusting for the period of
follow-up in the clinic (which was relatively longer for long-
term users of OCs) the statistical significance of this
association disappeared. No differences were found across
categories of time since last use of OCs, ever/never use of
OCs and ever/never use of different methods ofcontraception
at entry to the cohort. Although we cannot be sure that clinic
smear frequency for controls was representative of the smearOral contraceptives and cervical cancer
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frequency during the total follow-up period, these data
provide some reassurance regarding the chance of a
detection bias having occurred. Moreover, if a detection
bias had been operating, and OC users had undergone
cervical smearing more frequently than users of other
methods, this would have tended to increase the chances of
diagnosis ofless severe lesions (Hulka, 1989). The highest risk
associated with OC use was observed in the invasive
carcinoma group, whereas the lowest risk was observed in
the dysplasia group. This pattern is not likely to be explained
by a detection bias.
The results of this nested case-control study largely
confirm the findings of our previous report (Vessey et al.,
1983), but provide a better insight into the relationship
between different aspects of OC use and cervical neoplasia.
The results suggest that current/recent, long-term users of
OCs may have an elevated risk of cervical neoplasia, in
particular of invasive carcinoma and carcinoma in situ.
Although we cannot rule out residual confounding by sexual
factors and we could not adjust for the possible effect ofHPV
infection, these findings provide independent support for an
effect of OCs which appears to operate in the later stages of
cervical carcinogenesis.
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